Provided by Tiger Trade Technology Pte. Ltd.

Axsome Therapeutics

211.12
+0.48500.23%
Post-market: 211.370.2541+0.12%17:36 EDT
Volume:526.37K
Turnover:110.81M
Market Cap:11.06B
PE:-56.02
High:211.65
Open:210.63
Low:208.01
Close:210.63
52wk High:260.19
52wk Low:112.90
Shares:52.38M
Float Shares:43.83M
Volume Ratio:1.09
T/O Rate:1.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7685
EPS(LYR):-3.6821
ROE:-245.10%
ROA:-16.31%
PB:132.75
PE(LYR):-57.34

Loading ...

Earnings Preview: Axsome Therapeutics revenue is expected to increase by 59.11%, and institutional views are broadly bullish

Earnings Agent
·
Apr 27

Axsome Therapeutics announces annual shareholder meeting via virtual webcast

Reuters
·
Apr 25

Axsome Chief Commercial Officer Ari Maizel disposes of common shares worth $1.37 million

Reuters
·
Apr 24

Axsome Therapeutics Facing 'Attractive Setup' Ahead of Auvelity's Label Expansion Decision, Oppenheimer Says

MT Newswires Live
·
Apr 21

Axsome Therapeutics Is Maintained at Buy by UBS

Dow Jones
·
Apr 11

Axsome Therapeutics Upside Tied to Auvelity FDA Decision, $2 Billion Sales Opportunity Seen, UBS Says

MT Newswires Live
·
Apr 10

UBS Adjusts Axsome Therapeutics Price Target to $259 From $251, Maintains Buy Rating

MT Newswires Live
·
Apr 10

Jefferies Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)

TIPRANKS
·
Apr 09

Axsome Therapeutics: Auvelity’s Best‑in‑Class Potential in Alzheimer’s Agitation Supports Buy Rating

TIPRANKS
·
Apr 09

Axsome Therapeutics to report first-quarter results, host conference call

Reuters
·
Apr 08

Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4

GlobeNewswire
·
Apr 08

RBC Capital Adjusts Price Target on Axsome Therapeutics to $221 From $222, Maintains Outperform Rating

MT Newswires Live
·
Apr 07

Analysts Offer Insights on Healthcare Companies: Imunon (IMNN), Axsome Therapeutics (AXSM) and Oric Pharmaceuticals (ORIC)

TIPRANKS
·
Apr 02

BUZZ-U.S. STOCKS ON THE MOVE-Eli Lilly, Space stocks, Anixa Biosciences

Reuters
·
Apr 02

BUZZ-U.S. STOCKS ON THE MOVE-Seagate, nCino, Zymeworks

Reuters
·
Apr 01

Axsome buys global rights to Takeda schizophrenia drug candidate balipodect (TAK-063)

Reuters
·
Apr 01

Axsome Therapeutics Inc - to Begin Phase 3 Trial-Enabling Activities for Schizophrenia in 2026

THOMSON REUTERS
·
Apr 01

Axsome Therapeutics Inc - Obtains Exclusive Global Rights to Balipodect From Takeda

THOMSON REUTERS
·
Apr 01

Axsome Therapeutics Inc - Takeda Receives Upfront Payment, Eligible for Milestone Payments and Royalties

THOMSON REUTERS
·
Apr 01

Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions

GlobeNewswire
·
Apr 01